Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Igor Stukalin(University of Calgary), Daniel Yick Chin Heng(University of Calgary), J. Connor Wells(Queen's University), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Ravindran Kanesvaran(University of Ioannina), Ajjai Alva(Michigan Medicine), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jeffrey Graham(University of Calgary), D. Scott Ernst, Lori Wood(Dalhousie University), Simon Fu(BC Cancer Agency), Christian Kollmannsberger(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Sandy Srinivas(Stanford University), Neeraj Agarwal(University of Utah), Tri Le(Southwestern Medical Center), Ian D. Davis(Austin Health), Aaron R. Hansen(Princess Margaret Cancer Centre)
Journal of Clinical Oncology
February 20, 2018
10.1200/jco.2018.36.6_suppl.615
Cited by 2

Related Papers

The Immune Landscape of Cancer
|Immunity|2018|6.3k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k